Genome Biologics secures up to €9.8M in equity funding from the EIC Accelerator to accelerate development of its clinical programmes for the prevention of cardiotoxicity and heart damage – an area of huge unmet need within the EU and globally.
Genome Biologics enters into a research collaboration and exclusive license option agreement with AstraZeneca to identify drivers of cardiac regeneration and recovery in Myocardial Infarction, Heart Failure and Cardiotoxicity
Genome Biologics wins the 2021 European Awards in Medicine (Drug Development category) for developing therapies for Cardiovascular and Cardiometabolic disease.
Blue Knight is a joint initiative between Johnson & Johnson Innovation–JLABS and the Biomedical Advanced Research and Development Authority (BARDA, of the U.S. Department of Health and Human Services), that aims to stimulate and accelerate innovation to improve global health security. Genome Biologics is one of seven companies from across the globe selected to join Blue Knight.
Genome Biologics is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.